AFI 002Alternative Names: AFI-002
Latest Information Update: 29 Jul 2016
At a glance
- Originator Altus Formulation Inc
- Developer Altus Formulation Inc; Unknown
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Attention-deficit hyperactivity disorder
Most Recent Events
- 29 Jul 2016 Preclinical trials in Attention-deficit hyperactivity disorder in USA (PO)
- 29 Jul 2016 Preclinical trials in Attention-deficit hyperactivity disorder in Canada (PO)